Miyata Y, Nishida E (2008) Evaluating CK2 activity with the antibody specific for the CK2-phosphorylated form of a kinase-targeting cochaperone Cdc37. Mol Cell Biochem 316, 127-34 18566753

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S13-p - CDC37 (human) ▲

Modsite: VWDHIEVsDDEDETH SwissProt Entrez-Gene Orthologous residues CDC37 (human): S13‑p, CDC37 (mouse): S13‑p, CDC37 (rat): S13‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  cervical cancer, cervical squamous cell carcinoma Relevant cell lines - cell types - tissues:  COS (fibroblast), KB (squamous) Cellular systems studied:  cell lines Species studied:  green monkey Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE CK2A2 (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes TBB decrease serum no change compared to control IGF-1 no change compared to control anisomycin increase slight increase UV increase slight increase

S13-p - CDC37 (rat) ▲
Modsite: VWDHIEVsDDEDETH SwissProt Entrez-Gene Orthologous residues CDC37 (human): S13‑p, CDC37 (mouse): S13‑p, CDC37 (rat): S13‑p Characterization Enzymes shown to modify site in vitro:  Type Enzyme KINASE CK2A2 (human)